Urology
Volume 77, Issue 1 , Pages 211-216, January 2011

Novel Artificial Urinary Sphincter in the Canine Model: The Tape Mechanical Occlusive Device

  • Bahaa S. Malaeb

      Affiliations

    • Department of Urologic Surgery, University of Minnesota, Minneapolis, Minnesota
    • Corresponding Author InformationReprint requests: Bahaa S Malaeb, M.D., Department of Urologic Surgery, University of Minnesota, 420 Delaware Street Southeast, MMC 394, Minneapolis, MN 55407
  • ,
  • Sean P. Elliott

      Affiliations

    • Department of Urologic Surgery, University of Minnesota, Minneapolis, Minnesota
  • ,
  • Joseph Lee

      Affiliations

    • Department of Urologic Surgery, University of Minnesota, Minneapolis, Minnesota
  • ,
  • David W. Anderson

      Affiliations

    • GT Urological, LLC, Minneapolis, Minnesota
  • ,
  • Gerald W. Timm

      Affiliations

    • Department of Urologic Surgery, University of Minnesota, Minneapolis, Minnesota
    • GT Urological, LLC, Minneapolis, Minnesota

Received 2 February 2010; accepted 7 June 2010. published online 10 November 2010.

Objectives

To assess the functionality, occlusive efficiency, and biocompatibility of a novel artificial urinary sphincter, the tape mechanical occlusive device (TMOD), after implantation in a live canine model, as well as its occlusive efficiency and sizing parameters in human cadavers.

Methods

Three female canines underwent implantation of the TMOD at the level of the bladder neck. Functionality was assessed starting at 2 weeks after implantation and continued for ≤9 weeks. The TMODs were activated at 2 weeks and then deactivated for 3, 30-minute sessions daily to permit voiding. The urethral occlusion pressures and biocompatibility for systemic toxicity and the local tissue response were examined. Additionally, the TMOD was inserted in 3 male cadavers to determine the sizing parameters and to assess the urethral occlusion pressures using pressure profilometry.

Results

In the canine model, the urethral occlusion pressures increased from a range of 9-42 cm H2O with the TMOD deactivated to a range of 57-82 cm H2O with the TMOD activated. Pathologic examination revealed unremarkable pseudocapsular tissues surrounding the device. No histologic or structural evidence of systemic toxicity was observed. Sizing parameters similar to those of other urologic implants were confirmed in the male cadavers, and the urethral occlusion pressures increased from 24 to 30 cm H2O with the device deactivated to 61-105 cm H2O with the device activated.

Conclusions

The TMOD meets the current standards for an artificial urinary sphincter in terms of functionality, biocompatibility, and achieving desired occlusion pressures following chronic implantation. Additional testing in male canines followed by early human clinical trials is being contemplated.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 This research was performed with government support under SBIR grant 2 R44 DK07 6397-02 from the National Institutes of Health, Bethesda, MD.

PII: S0090-4295(10)01496-2

doi:10.1016/j.urology.2010.06.065

Urology
Volume 77, Issue 1 , Pages 211-216, January 2011